Subscribe

News
Academy
Multimedia
Conferences
Publications
Partner Perspectives
Resources
Subscribe

|Articles|June 26, 2015

GSK to Sell Legacy Vaccines to Pfizer

June 26, 2015.

GlaxoSmithKline has announced that it will sell its meningitis vaccines Nimenrix and Mencevax to Pfizer Ireland Pharmaceuticals. The €115m sale is subject to final European Commission approval, other regulatory approvals, and other customary closing conditions and is expected to close before the end of the year.

Source: GSK

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related Content

From Ambition to Advantage: How Life Sciences Leaders Are Scaling AI

ByShravan Kotakonda

December 10th 2025

Stock.adobe.com

Aidoc Submits Breakthrough-Designated Multi-Triage Device for FDA Approval

ByNicholas Jacobus

November 25th 2025

Jo Varshney

How Technology is Moving the Industry Away from Animal Testing: Q&A with Dr. Jo Varshney

November 25th 2025

Stock.adobe.com

Agentic AI Will Transform the Business of Life Sciences

November 18th 2025

Anup Gupta

Pharma’s Next Commercial Frontier: Orchestrating Data, AI, and CRM for True Customer Centricity

November 6th 2025

Trending on PharmExec

Brent Saunders: Eyeing New Horizons

TrumpRX Has a Blind Spot and It Can Redefine Patient Access

FDA Grants National Priority Voucher to Tecvayli Combination in Relapsed or Refractory Multiple Myeloma

Sobi Reaches $1.5 Billion Definitive Agreement with Arthrosi Therapeutics to Acquire Gout Treatment

FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies

© 2025 MJH Life Sciences^®

All rights reserved.